The Technical Analyst
Cabaletta Bio Inc [CABA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cabaletta Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-7.79% $13.97
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 673.94 mill |
| EPS: | -1.650 |
| P/E: | -8.47 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 48.24 mill |
| Avg Daily Volume: | 0.954 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.47 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.44x |
| Company: PE -8.47 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.60 (-67.10%) $-9.37 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 12.65 - 15.25 ( +/- 9.29%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Gerard Michael | Buy | 100 000 | Stock Option (Right to Buy) |
| 2024-03-01 | Chang David J. | Buy | 130 000 | Stock Option (Right to Buy) |
| 2024-03-01 | Nichtberger Steven | Buy | 353 000 | Stock Option (Right to Buy) |
| 2024-03-01 | Marda Anup | Buy | 130 000 | Stock Option (Right to Buy) |
| 2024-03-01 | Das Arun | Buy | 100 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 82.33 |
| Last 97 transactions |
| Buy: 4 947 826 | Sell: 1 979 584 |
Forecast:
16:00 - $13.97
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $13.97
Forecast 2: 16:00 - $13.97
Forecast 3: 16:00 - $13.97
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.97 (-7.79% ) |
| Volume | 1.145 mill |
| Avg. Vol. | 0.954 mill |
| % of Avg. Vol | 120.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CABA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.48 | N/A | Active |
|---|
CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Latest Press Releases
2024-03-21 07:00:00 - Press Release
Cabaletta Bio Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
– first patient dosed with caba-201 in the reset™ (restoring self-tolerance) clinical trial program – – initial clinical data from each of the first patients in the reset-myositis™ and reset-sle™ trials anticipated in 1h24; longer term follow-up on these and additional patients to be reported in 2h24 – – reset-ssc™ (systemic sclerosis) and reset-mg™ trials initial clinical data anticipated to be reported in 2h24 – – rare pediatric disease designation granted by fda for caba-201 in juvenile dermatomyositis – – cash runway into 1h26 with cash, cash equivalents and short-term investments of $241.2 million as of december 31, 2023 – philadelphia, march 21, 2024 (globe newswire) -- cabaletta bio, inc...
2024-02-27 08:00:00 - Press Release
Cabaletta Bio To Participate In Upcoming Investor Conferences In March
Philadelphia, feb. 27, 2024 (globe newswire) -- cabaletta bio, inc. (nasdaq: caba), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the company will participate in two upcoming investor conferences in march:
2024-02-01 16:30:00 - Press Release
Cabaletta Bio Announces Fda Granted Orphan Drug Designation To Caba-201 For Treatment Of Myositis
Philadelphia, feb. 01, 2024 (globe newswire) -- cabaletta bio, inc. (nasdaq: caba), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to caba-201, a 4-1bb-containing fully human cd19-car t cell investigational therapy, for the treatment of idiopathic inflammatory myopathies (iim, or myositis). caba-201 is in development as a potential treatment for autoimmune diseases driven by b cells. four reset™ (restoring self-tolerance) phase 1/2 trials are advancing for the evaluation of caba-201 across multiple autoimmune conditions, including the phase 1/2 reset-myositis™ trial.
2024-01-31 08:00:00 - Press Release
Cabaletta Bio To Participate In The Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Philadelphia, jan. 31, 2024 (globe newswire) -- cabaletta bio, inc. (nasdaq: caba), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that steven nichtberger, m.d., chief executive officer, will participate in a fireside chat at the guggenheim healthcare talks 6th annual biotechnology conference on wednesday, february 7, 2024 at 10:00 a.m. et in new york, ny.
2024-01-02 08:00:00 - Press Release
Cabaletta Bio To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Philadelphia, jan. 02, 2024 (globe newswire) -- cabaletta bio, inc. (nasdaq: caba), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that steven nichtberger, m.d., chief executive officer, will present at the 42nd annual j.p. morgan healthcare conference on tuesday, january 9, 2024, at 5:15 p.m. pt (8:15 p.m. et) in san francisco, ca.
Latest News
2024-01-31 02:53:09 - Seeking Alpha
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024.
2023-12-10 02:44:26 - Seeking Alpha
Buy Cabaletta Bio's Promising SLE Treatment
Cabaletta Bio is a biotech company with promising CARTA and CAART therapies for autoimmune diseases. Their main research project, CABA-201, targets patients suffering from SLE, opening up a huge market with significant revenue potential. The company is well-capitalized and has a cash runway that extends beyond 2025, making it a good long-term investment.
2023-11-28 15:55:00 - Market Watch
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administration said it was investigating cancer risks potentially associated with all currently approved products in the class.
2023-10-30 08:00:00 - GlobeNewsWire
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in three upcoming investor conferences in November:
2023-10-09 11:17:28 - Zacks Investment Research
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
2023-09-25 10:31:52 - Zacks Investment Research
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2023-09-19 08:00:00 - GlobeNewsWire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:
2023-09-19 04:56:57 - Seeking Alpha
Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?
Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than oncology, has been a key factor in its success. Cabaletta's cell therapy CABA-201 targeting Lupus Nephritis has had its MoA validated by an academic study, leading to increased investor interest and a rise in share price.
2023-09-08 10:32:48 - Zacks Investment Research
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2023-08-31 08:30:53 - InvestorPlace
The 7 Most Promising Momentum Stocks to Own Now
Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum investing hinges on the principle that assets that have performed well recently will continue to do so in the near future.